Patients
Our mission is to make a life-changing impact on patients with cancer and other diseases.

Patients

Our mission is to make a life-changing impact on patients with cancer and other diseases.

Commitment

Our strategy to benefit patients is to create breakthrough medicines designed to transform how cancer is treated. The versatility of the Bicycle technology allows us to develop medicines that target cancer in a unique, fast and specific way.

While excellent progress has been made in cancer therapeutics, most patients with metastatic disease remain incurable. Bicycle’s therapeutic focus is patients with the most aggressive cancers, such as pancreatic, triple negative breast cancer, lung cancer and gastric cancer. In addition, several less common tumours such as sarcomas, gastric or head and neck cancers, and orphan tumours continue to have few options for therapy, and only some of those tumours respond to current therapeutic/immunologic approaches. We are committed to improving the lives of patients with these difficult-to-treat tumours.

Cancer Research UK Partnership

We have partnered with Cancer Research UK, the world’s largest cancer charity and a leading research organization, to rapidly advance our lead candidate, BT1718, for the treatment of cancers including sarcoma, triple negative breast cancer, and non small cell lung cancer.

Cancer Research UK has an impressive track record of discovering and developing novel treatments for cancer, with the organization’s Centre for Drug Development (CDD) having taken over 140 agents into early clinical trials. Five of these are now marketed drugs. This collaboration provides Bicycle with access to Cancer Research UK’s extensive oncology expertise as we robustly test our lead asset in patients for the first time, while putting Cancer Research UK at the forefront of the development of a potentially disruptive new class of anti-cancer agents.

The CDD is funding and sponsoring Phase 1 and Phase 2a clinical trials for BT1718, which are co-managed. Bicycle retains the right to further advance BT1718, in return for success-based milestones, equity and royalty payments that can be re-invested in other life-saving research undertaken by Cancer Research UK.